Comparing Bivalirudin Versus Heparin/ GP IIB/IIA in Patients Undergoing PCI

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2007 by Gold, Herman K., MD.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
The Medicines Company
Information provided by:
Gold, Herman K., MD
ClinicalTrials.gov Identifier:
NCT00476944
First received: May 18, 2007
Last updated: NA
Last verified: May 2007
History: No changes posted
  Purpose

The purpose of this study is to compare the rates of vascular related complications in patients undergoing percutaneous coronary intervention assigned to one of two arms: 1) bivalirudin + provisional Gp IIB/IIIA use versus 2) heparin + Gp IIB/IIIA (eptifibatide (Integrilin®)) use.


Condition Intervention Phase
Coronary Artery Disease
Procedure: Percutaneous Coronary Intervention (PCI)
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Official Title: Minimizing Post-Procedural Vascular Complications: Comparing Bivalirudin Versus Heparin/GP IIB/IIA in Patients Undergoing Percutaneous Coronary Intervention

Resource links provided by NLM:


Further study details as provided by Gold, Herman K., MD:

Primary Outcome Measures:
  • Number of patients who require a vascular groin ultrasound or abdominal CT.
  • Record occurrence of pseudoaneurysm, arteriovenous fistula, retroperitoneal hematoma, or femoral vein or arterial thrombosis
  • Record presence of hematoma and size if applicable.
  • Record hemoglobin drop >3g/dl with over bleeding. Also, record any red cell transfusion due to catheterization related bleeding.

Secondary Outcome Measures:
  • Comparison of time to ambulation.
  • Occurrence of major and minor bleeding peri-catheterization.
  • Observe incidence of thrombocytopenia post catheterization defined as a platelet count <100,000.

Study Start Date: September 2006
Detailed Description:

Anti-thrombotic therapies have enhanced the safety of percutaneous coronary intervention (PCI). In addition to aspirin, heparin and platelet glycoprotein (Gp) IIB/IIIA receptor inhibition have been used as the reference strategy to reduce the incidence of ischemic complications during coronary interventions 1. However, the success of this strategy is limited by increased bleeding risk, prolonged drug infusions (12 hours), and patient inconveniences (such as lying flat for hours until blood coagulation becomes normal and sheaths can be safely removed). Peri-procedural bleeding due to vascular complications is one of the most frequent complications of PCI and is associated with adverse events 2.

Newer anti-thrombotic strategies may further improve outcomes after PCI. The efficacy of a direct thrombin inhibitor bivalirudin (Angiomax™) was investigated in a randomized controlled clinical trial as a replacement for the strategy of heparin/Gp IIB/IIIA inhibition in patients undergoing coronary intervention. The REPLACE-2 study, which randomized over 6000 patients found short and long-term clinical outcomes with bivalirudin were as effective as heparin/Gp IIB/IIIA inhibition combination with evidence of significantly less major and minor bleeding 3, 4. This led to approval of the 0.75 mg/kg/1.75 mg/kg/hr dose of Angiomax® by the Food and Drug Administration for use as an anticoagulant in patients with unstable angina undergoing PCI.

It is now routinely accepted that early sheath removal after PCI reduces femoral access site complications and leads to earlier ambulation, earlier discharge, improved patient satisfaction 5. Heparin-based anticoagulation requires monitoring of the coagulation status to determine readiness for sheath removal because of the lack of predictable duration of anticoagulation with heparin. Because clearance of bivalirudin occurs mostly by proteolytic cleavage by thrombin, the drug has more predictable pharmacokinetics and exhibits linear dose relationship with respect to plasma concentrations and coagulation assay endpoints 6. Preliminary studies indicate sheath removal 2 hours after cessation of bivalirudin without coagulation monitoring is safe 5. While REPLACE-2 suggested that catheterization related vascular complications were decreased with bivalirudin, specific data on these endpoints and others such as time to ambulation and time to discharge were not collected because of the blinded nature of the trial. Currently the rate of vascular complications at MGH for patients undergoing PCI is 4.0% which significantly exceeds the national rate of 1.9% (95% CI 1.1 to 3.2) 7.

We will conduct a randomized clinical trial in patients undergoing PCI to compare the rates of vascular related complications between patients assigned to one of two arms: 1) bivalirudin + provisional Gp IIB/IIIA use versus 2) heparin + Gp IIB/IIIA (eptifibatide (Integrilin®)) use. The primary endpoint will be a composite of vascular related groin complications (MAVE-major adverse vascular endpoints as defined in next section). Secondary endpoints will be 1) time to sheath pull; 2) time to ambulation; and 3) occurrence of major and minor bleeding peri-catheterization.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Patients must meet ALL of the following criteria:

  • The patients must be >18 years of age
  • Patients must have been referred for percutaneous coronary intervention (PCI)
  • Diagnosis of angina pectoris defined by Canadian Cardiovascular Society Classification (CCS I, II, III, IV) OR unstable angina pectoris (Braunwald Classification B&C, I-II-III) OR patients with documented silent ischemia;
  • Treatment of lesions in native coronary vessels or bypass grafts requiring angioplasty or stenting.
  • Patient is willing to comply with the specified follow-up evaluation;
  • Patient must provide written informed consent prior to the procedure using a form that is approved by the local Institutional Review Board.

Exclusion Criteria:

Patients will be excluded if ANY of the following conditions apply:

  • Patient has experienced an ST-segment elevation myocardial infarction within the preceding 24 hours.
  • Active internal bleeding or bleeding diathesis, surgery, trauma, or gastrointestinal or genitourinary tract bleeding within past 6 weeks; prior intracranial bleeding; or platelet count<100,000
  • Woman of child-bearing potential unless demonstrated negative pregnancy test
  • End Stage Renal Disease requiring hemodialysis
  • Recipient of heart transplant;
  • Current treatment with 1) intravenous unfractionated heparin or treatment with low molecular weight heparin within past 8 hours; 2)bivalirudin; 3)abciximab; 4)eptifibatide; or tirofiban
  • Ongoing need for warfarin or heparin therapy
  • Known allergies to aspirin, clopidogrel bisulfate (Plavix®) and/or heparin;
  • Any significant medical condition which in the investigator’s opinion may interfere with the patient’s optimal participation in the study;
  • Currently participating in an investigational drug or another device study;
  • Any contraindication to glycoprotein IIb/IIIa inhibitor (eptifibatide (Integrilin®)) or bivalirudin therapy;
  • Chronic or relapse/remitting hemolytic condition or pre-catheterization hematocrit<30 mg/dl
  • Unprotected left main coronary disease with >50% stenosis;
  • Platelet count <150,000
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00476944

Contacts
Contact: Maureen Daher, RN 617-726-7400 MDAHER@PARTNERS.ORG
Contact: Jae S Oh, BSc 617-643-0456 JSOH@PARTNERS.ORG

Locations
United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Principal Investigator: Herman K Gold, MD         
Sub-Investigator: Aloke V Finn, MD         
Sub-Investigator: Igor F Palacios, MD         
Sub-Investigator: Robert C. Leinbach, MD         
Sub-Investigator: Kenneth Rosenfield, MD         
Sub-Investigator: Joseph Garasic, MD         
Sub-Investigator: Eugene Pomerantsev, MD, PhD         
Sub-Investigator: Ignacio Inglessis, MD         
Sub-Investigator: Farouc A Jaffer, MD, PhD         
Sub-Investigator: Andrew Maree, MD         
Sub-Investigator: George T Lau, MD         
Sub-Investigator: Owen C Raffel, MD         
Sub-Investigator: Leon M Ptaszek, MD         
Sub-Investigator: Vishal Gupta, MD         
Sub-Investigator: Maureen Daher, RN         
Sub-Investigator: Jae S Oh, BSc         
Sponsors and Collaborators
Gold, Herman K., MD
The Medicines Company
Investigators
Principal Investigator: Herman K Gold, MD Massachusetts General Hospital
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00476944     History of Changes
Other Study ID Numbers: 2006P000944
Study First Received: May 18, 2007
Last Updated: May 18, 2007
Health Authority: United States: Food and Drug Administration

Keywords provided by Gold, Herman K., MD:
CAD
Coronary Artery Disease
Angiomax
Bivalirudin
PCI
MAVE
Heparin

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Bivalirudin
Heparin
Anticoagulants
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Cardiovascular Agents
Antithrombins
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors

ClinicalTrials.gov processed this record on August 27, 2014